Hyloris Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Hyloris Pharmaceuticals's earnings have been declining at an average annual rate of -25.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 116.3% per year.
Key information
-25.7%
Earnings growth rate
-5.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 116.3% |
| Return on equity | -24.1% |
| Net Margin | -374.0% |
| Next Earnings Update | 01 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hyloris Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 3 | -12 | 3 | 5 |
| 30 Sep 21 | 2 | -12 | 2 | 4 |
| 30 Jun 21 | 1 | -12 | 1 | 3 |
| 31 Mar 21 | 1 | -10 | 2 | 3 |
| 31 Dec 20 | 0 | -7 | 2 | 3 |
| 30 Sep 20 | 0 | -8 | 3 | 2 |
| 30 Jun 20 | 0 | -8 | 3 | 2 |
| 31 Mar 20 | 0 | -6 | 1 | 2 |
| 31 Dec 19 | 0 | -5 | 1 | 1 |
| 31 Dec 18 | 0 | -6 | 1 | 5 |
| 31 Dec 17 | 0 | -4 | 2 | 2 |
Quality Earnings: 52U is currently unprofitable.
Growing Profit Margin: 52U is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 52U is unprofitable, and losses have increased over the past 5 years at a rate of 25.7% per year.
Accelerating Growth: Unable to compare 52U's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 52U is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 52U has a negative Return on Equity (-24.09%), as it is currently unprofitable.